Kumar Neil 4

What Happened

• Neil Kumar, CEO of BridgeBio Pharma, was granted two equity awards on March 17, 2026: 40,570 derivative shares (option grant) and 104,313 Restricted Stock Units (RSUs). Both grants are reported at an acquisition price of $0.00. These were reported on a Form 4 filed March 19, 2026.
• This was an award/grant (transaction code A), not an open‑market buy or sale. No cash changed hands at grant; the awards are contingent on future vesting and continued service.

Key Details

• Transaction date: 2026-03-17; Form 4 filed: 2026-03-19 (timely).
• Grants: 40,570 (derivative option) and 104,313 RSUs; both reported at $0.00.
• Total shares awarded: 144,883.
• Vesting: For the option (F1) and RSUs (F3) the schedule is 1/16th vesting on May 16, 2026, then 1/16th vesting quarterly thereafter, subject to continued service. RSUs represent a contingent right to one share each (F2) and the RSUs have no expiration date.
• Shares owned after the transaction are not specified in the provided excerpt.
• No 10b5-1 plan, tax‑withholding, or late‑filing notes are indicated in the excerpt.

Context

• These grants are typical executive compensation: RSUs convert into shares on vesting, and the option becomes exercisable per the vesting schedule. Because these are awards (not purchases or sales), they do not reflect an immediate cash investment or divestment by the CEO.